-
Something wrong with this record ?
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable
S. Georgiadis, LM. Ørnbjerg, B. Michelsen, TK. Kvien, D. Di Giuseppe, JK. Wallman, J. Závada, SA. Provan, EK. Kristianslund, AM. Rodrigues, MJ. Santos, Ž. Rotar, KP. Pirkmajer, D. Nordström, GJ. Macfarlane, GT. Jones, I. van der Horst-Bruinsma,...
Language English Country Canada
Document type Journal Article
- MeSH
- Spondylitis, Ankylosing * blood diagnosis MeSH
- Axial Spondyloarthritis * blood diagnosis MeSH
- C-Reactive Protein * analysis MeSH
- Adult MeSH
- Blood Sedimentation * MeSH
- Middle Aged MeSH
- Humans MeSH
- Registries MeSH
- Severity of Illness Index * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVE: Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). Although ASDAS-CRP and ASDAS-ESR are not interchangeable, the same disease activity cut-offs are used for both. We aimed to estimate optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs (1.3, 2.1, and 3.5) and investigate the potential improvement of level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states when applying these estimated cut-offs. METHODS: We used data from patients with axSpA from 9 European registries initiating a tumor necrosis factor inhibitor. ASDAS-ESR cut-offs were estimated using the Youden index. The level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states was compared against each other. RESULTS: In 3664 patients, mean ASDAS-CRP was higher than ASDAS-ESR at both baseline (3.6 and 3.4, respectively) and aggregated follow-up at 6, 12, or 24 months (1.9 and 1.8, respectively). The estimated ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs were 1.4, 1.9, and 3.3. By applying these cut-offs, the proportion of discordance between disease activity states according to ASDAS-ESR and ASDAS-CRP decreased from 22.93% to 19.81% in baseline data but increased from 27.17% to 28.94% in follow-up data. CONCLUSION: We estimated the optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-off values. However, applying the estimated cut-offs did not increase the level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states to a relevant degree. Our findings did not provide evidence to reject the established cut-off values for ASDAS-ESR.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019928
- 003
- CZ-PrNML
- 005
- 20241024110843.0
- 007
- ta
- 008
- 241015s2024 xxc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3899/jrheum.2023-1217 $2 doi
- 035 __
- $a (PubMed)38621792
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxc
- 100 1_
- $a Georgiadis, Stylianos $u S. Georgiadis, PhD, L.M. Ørnbjerg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; stylianos.georgiadis@regionh.dk $1 https://orcid.org/0000000334859457
- 245 10
- $a Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable / $c S. Georgiadis, LM. Ørnbjerg, B. Michelsen, TK. Kvien, D. Di Giuseppe, JK. Wallman, J. Závada, SA. Provan, EK. Kristianslund, AM. Rodrigues, MJ. Santos, Ž. Rotar, KP. Pirkmajer, D. Nordström, GJ. Macfarlane, GT. Jones, I. van der Horst-Bruinsma, P. Hellamand, M. Østergaard, ML. Hetland
- 520 9_
- $a OBJECTIVE: Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). Although ASDAS-CRP and ASDAS-ESR are not interchangeable, the same disease activity cut-offs are used for both. We aimed to estimate optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs (1.3, 2.1, and 3.5) and investigate the potential improvement of level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states when applying these estimated cut-offs. METHODS: We used data from patients with axSpA from 9 European registries initiating a tumor necrosis factor inhibitor. ASDAS-ESR cut-offs were estimated using the Youden index. The level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states was compared against each other. RESULTS: In 3664 patients, mean ASDAS-CRP was higher than ASDAS-ESR at both baseline (3.6 and 3.4, respectively) and aggregated follow-up at 6, 12, or 24 months (1.9 and 1.8, respectively). The estimated ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs were 1.4, 1.9, and 3.3. By applying these cut-offs, the proportion of discordance between disease activity states according to ASDAS-ESR and ASDAS-CRP decreased from 22.93% to 19.81% in baseline data but increased from 27.17% to 28.94% in follow-up data. CONCLUSION: We estimated the optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-off values. However, applying the estimated cut-offs did not increase the level of agreement between ASDAS-ESR and ASDAS-CRP disease activity states to a relevant degree. Our findings did not provide evidence to reject the established cut-off values for ASDAS-ESR.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a C-reaktivní protein $x analýza $7 D002097
- 650 12
- $a krevní sedimentace $7 D001799
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a ankylózující spondylitida $x krev $x diagnóza $7 D013167
- 650 12
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a axiální spondyloartritida $x krev $x diagnóza $7 D000089183
- 650 _2
- $a registrace $7 D012042
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ørnbjerg, Lykke Midtbøll $u S. Georgiadis, PhD, L.M. Ørnbjerg, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000278326831
- 700 1_
- $a Michelsen, Brigitte $u B. Michelsen, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, and Research Unit, Sørlandet Hospital, Kristiansand, Norway, and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark $1 https://orcid.org/0000000301032840
- 700 1_
- $a Kvien, Tore K $u T.K. Kvien, MD, PhD, E.K. Kristianslund, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $1 https://orcid.org/0000000284413093
- 700 1_
- $a Di Giuseppe, Daniela $u D. Di Giuseppe, PhD, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000338178288
- 700 1_
- $a Wallman, Johan K $u J.K. Wallman, MD, PhD, Department of Clinical Sciences Lund, Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden $1 https://orcid.org/0000000249152924
- 700 1_
- $a Závada, Jakub $u J. Závada, MD, PhD, Institute of Rheumatology, Prague, Czech Republic and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000298026545 $7 xx0160054
- 700 1_
- $a Provan, Sella A $u S.A. Provan, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, and Public Health Section, Inland Norway University of Applied Sciences, Elverum, Norway $1 https://orcid.org/000000015442902X
- 700 1_
- $a Kristianslund, Eirik Klami $u T.K. Kvien, MD, PhD, E.K. Kristianslund, MD, PhD, Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway $1 https://orcid.org/0000000249633285
- 700 1_
- $a Rodrigues, Ana Maria $u A.M. Rodrigues, MD, PhD, EpiDoC Unit, CEDOC, Nova Medical School, and Rheumatology Unit, Hospital dos Lusíadas, Lisbon, Portugal $1 https://orcid.org/0000000320468017
- 700 1_
- $a Santos, Maria José $u M.J. Santos, MD, PhD, Department of Rheumatology, Hospital Garcia de Orta, Almada, and Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal $1 https://orcid.org/0000000279461365
- 700 1_
- $a Rotar, Žiga $u Ž. Rotar, MD, PhD, K. Perdan Pirkmajer, MD, Department of Rheumatology, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/0000000293239189
- 700 1_
- $a Pirkmajer, Katja Perdan $u Ž. Rotar, MD, PhD, K. Perdan Pirkmajer, MD, Department of Rheumatology, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/0000000177784016
- 700 1_
- $a Nordström, Dan $u D. Nordström, MD, PhD, Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/0000000236616072
- 700 1_
- $a Macfarlane, Gary J $u G.J. Macfarlane, MD, PhD, G.T. Jones, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000323223314
- 700 1_
- $a Jones, Gareth T $u G.J. Macfarlane, MD, PhD, G.T. Jones, PhD, Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK $1 https://orcid.org/0000000300167591
- 700 1_
- $a van der Horst-Bruinsma, Irene $u I. van der Horst-Bruinsma, MD, PhD, Rheumatology, Radboud University Medical Center, Nijmegen, the Netherlands $1 https://orcid.org/0000000280869915
- 700 1_
- $a Hellamand, Pasoon $u P. Hellamand, MD, Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, Netherlands and Amsterdam Rheumatology Immunology Center, Reade, and Amsterdam UMC, Amsterdam, the Netherlands $1 https://orcid.org/0000000222513435
- 700 1_
- $a Østergaard, Mikkel $u M. Østergaard, MD, PhD, DMSc, M.L. Hetland, MD, PhD, DMSc, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/000000033690467X
- 700 1_
- $a Hetland, Merete Lund $u M. Østergaard, MD, PhD, DMSc, M.L. Hetland, MD, PhD, DMSc, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark $1 https://orcid.org/0000000342296818
- 773 0_
- $w MED00002935 $t The Journal of rheumatology $x 1499-2752 $g Roč. 51, č. 7 (2024), s. 673-677
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38621792 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110837 $b ABA008
- 999 __
- $a ok $b bmc $g 2202257 $s 1231901
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 51 $c 7 $d 673-677 $e 20240701 $i 1499-2752 $m The Journal of rheumatology $n J Rheumatol $x MED00002935
- LZP __
- $a Pubmed-20241015